68 related articles for article (PubMed ID: 20699624)
21. [Unresectable gallbladder cancer with lymph node and liver metastases completely responding to S-1 monotherapy - a case report].
Furuse J; Nakachi K; Suzuki E; Shimizu S; Ishii H; Yoshino M
Gan To Kagaku Ryoho; 2007 Oct; 34(10):1679-82. PubMed ID: 17940390
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
[TBL] [Abstract][Full Text] [Related]
23. A late phase II study of S-1 for metastatic pancreatic cancer.
Okusaka T; Funakoshi A; Furuse J; Boku N; Yamao K; Ohkawa S; Saito H
Cancer Chemother Pharmacol; 2008 Apr; 61(4):615-21. PubMed ID: 17520253
[TBL] [Abstract][Full Text] [Related]
24. High response rates in patients with pancreatic cancer using the novel oral fluoropyrimidine S-1.
Hayashi K; Imaizumi T; Uchida K; Kuramochi H; Takasaki K
Oncol Rep; 2002; 9(6):1355-61. PubMed ID: 12375048
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
Rago RP; Einstein A; Lush R; Beer TM; Ko YJ; Henner WD; Bubley G; Merica EA; Garg V; Ette E; Harding MW; Dalton WS
Cancer Chemother Pharmacol; 2003 Apr; 51(4):297-305. PubMed ID: 12721757
[TBL] [Abstract][Full Text] [Related]
26. A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer.
Flaig TW; Barqawi A; Miller G; Kane M; Zeng C; Crawford ED; Glodé LM
Cancer; 2006 Jul; 107(2):266-74. PubMed ID: 16779800
[TBL] [Abstract][Full Text] [Related]
27. [Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer].
Yumine K; Kawahara M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():189-92. PubMed ID: 16898000
[TBL] [Abstract][Full Text] [Related]
28. Clinical efficacy of S-1 in pretreated metastatic breast cancer patients.
Shien T; Shimizu C; Akashi-Tanaka S; Yonemori K; Kohno T; Hojo T; Ando M; Katsumata N; Kinoshita T; Fujiwara Y
Jpn J Clin Oncol; 2008 Mar; 38(3):172-5. PubMed ID: 18296424
[TBL] [Abstract][Full Text] [Related]
29. A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group.
Moore MM; Stockler M; Lim R; Mok TS; Millward M; Boyer MJ
Cancer Chemother Pharmacol; 2010 Oct; 66(5):845-50. PubMed ID: 20082080
[TBL] [Abstract][Full Text] [Related]
30. A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer.
Morris MJ; Kelly WK; Slovin S; Ryan C; Eicher C; Heller G; Scher HI
J Urol; 2007 Dec; 178(6):2378-83; discussion 2383-4. PubMed ID: 17936848
[TBL] [Abstract][Full Text] [Related]
31. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of sorafenib in patients with castrate resistant prostate cancer: a Phase II study.
Safarinejad MR
Urol Oncol; 2010; 28(1):21-7. PubMed ID: 18789732
[TBL] [Abstract][Full Text] [Related]
33. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
[TBL] [Abstract][Full Text] [Related]
34. A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301 study).
Kodera Y; Ito S; Mochizuki Y; Kondo K; Koshikawa K; Suzuki N; Kojima H; Kojima T; Matsui T; Takase T; Tsuboi K; Fujiwara M; Nakao A;
Eur J Surg Oncol; 2009 Nov; 35(11):1158-63. PubMed ID: 19328643
[TBL] [Abstract][Full Text] [Related]
35. Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen.
Narimoto K; Mizokami A; Izumi K; Mihara S; Sawada K; Sugata T; Shimamura M; Miyazaki K; Nishino A; Namiki M
Int J Urol; 2010 Apr; 17(4):337-45. PubMed ID: 20202011
[TBL] [Abstract][Full Text] [Related]
36. An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer.
Pezaro C; Rosenthal MA; Gurney H; Davis ID; Underhill C; Boyer MJ; Kotasek D; Solomon B; Toner GC
Am J Clin Oncol; 2009 Aug; 32(4):338-41. PubMed ID: 19363437
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of adjuvant chemotherapy with S-1 for colorectal liver metastasis.
Uehara K; Maeda A; Sakamoto E; Hiramatsu K; Takeuchi E; Sakaguchi K; Tojima Y; Takahashi Y; Ebata T; Nagino M
Ann Surg Oncol; 2013 Feb; 20(2):475-81. PubMed ID: 22965575
[TBL] [Abstract][Full Text] [Related]
38. [Results of chemotherapy in head and neck cancer patients with residual or recurrent tumors after initial treatment].
Katsuno M; Watanabe N; Sugio Y; Tachibana S; Tani Y; Sato N; Zusho H
Gan To Kagaku Ryoho; 2010 Nov; 37(11):2109-13. PubMed ID: 21084809
[TBL] [Abstract][Full Text] [Related]
39. Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus Doxorubicin in the treatment of metastatic castration-resistant prostate cancer.
Slovin SF; Kelly WK; Wilton A; Kattan M; Myskowski P; Mendelsohn J; Scher HI
Clin Genitourin Cancer; 2009 Oct; 7(3):E77-82. PubMed ID: 19815486
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of fulvestrant (Faslodex) in castration resistant prostate cancer.
Chadha MK; Ashraf U; Lawrence D; Tian L; Levine E; Silliman C; Escott P; Payne V; Trump DL
Prostate; 2008 Sep; 68(13):1461-6. PubMed ID: 18618738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
